More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Posted innews Oncology Urology

More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer

Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while significantly increasing the risk of long-term gastrointestinal toxicity.
FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
Posted innews Oncology Urology

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations

The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survival benefits in the AMPLITUDE trial.